. Author manuscript; available in PMC: 2014 Jan 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):95–101. doi: 10.1097/QAI.0b013e3182785638

Table 2. Intervention scenarios.

Param.	VMB model			PrEP model
Scenario	Coverage	Resistance¹	Adherence²	Coverage	Resistance¹	Adherence²
Sc1	40%-50%	0.33-0.5	50%-60%	40%-50%	0.33-0.5	70%-80%
Sc2	40%-50%	0.33-0.5	70%-80%	40%-50%	0.33-0.5	90%-100%
Sc3	40%-50%	1-2	50%-60%	40%-50%	1-2	70%-80%
Sc4	40%-50%	1-2	70%-80%	40%-50%	1-2	90%-100%
Sc5	70%-80%	0.33-0.5	50%-60%	70%-80%	0.33-0.5	70%-80%
Sc6	70%-80%	0.33-0.5	70%-80%	70%-80%	0.33-0.5	90%-100%
Sc7	70%-80%	1-2	50%-60%	70%-80%	1-2	70%-80%
Sc8	70%-80%	1-2	70%-80%	70%-80%	1-2	90%-100%

Annual rate of resistance development (r_max).

The adherence metric assesses the proportion of sex acts in which each user is protected by VMB or the relative PrEP efficacy due to imperfect adherence compared to perfect adherence.

VMB, vaginal microbicides; PrEP, oral pre-exposure prophylaxis.